Updates are available Correction dated 2026-03-03
Click to view Correction: https://doi.org/10.1038/s41573-026-01409-3
-
Authors
Coyle, Joseph T.
Paul, Steven M. https://orcid.org/0009-0009-2773-8025
- License Information
-
More Information
Article History
Accepted: 3 November 2025
First Online: 8 January 2026
Change Date: 3 March 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41573-026-01409-3
Competing interests
: J.T.C. is a founder of Waveform Bioscience, a member of the Scientific Advisory Board of SyneuRx and a consultant to Response Pharmaceuticals. S.M.P. is a former employee and shareholder of Karuna Therapeutics (now Bristol Myers Squibb); a cofounder and shareholder of Sage Therapeutics, Voyager Therapeutics, Rapport Therapeutics and Seaport Therapeutics; a shareholder of Alnylam Pharmaceuticals and Eli Lilly and Company; and a venture partner at Third Rock Ventures. Since the inception of this manuscript, he has had no financial interests in Cobenfy and its marketing.
